“C. diff. Spores and More,” Global Broadcasting Network – innovative and educational interactive healthcare talk radio program discusses
This Episode: Rebiotix: The Leader in Unlocking the Benefits of Microbiota Restoration Therapy (MRT) “
With Our Guest: Lee Jones, Founder and CEO, Rebiotix
Join us today on C. diff. Spores and More discuss Rebiotix
with Rebiotix Founder, CEO Lee Jones. Listen in as we learn more about
the History, Company profile, the problems they are solving, and product information. Lee will explain What is the microbiome? Their first product RBX 2660 – addressing C. diff, with the Rebiotix platform called MRT (Microbiota Restoration Therapy) and how MRT is different
and much more.
MORE ABOUT OUR GUEST:
Lee Jones, CEO and Founder of Rebiotix Inc., is an experienced medical technology executive and serial entrepreneur. With deep experience in the medical devices industry and in managing and advising academic scientists on commercialization efforts, Rebiotix marks her first foray into biotechnology. She is leading a fast-paced effort to develop a new way of treating disease through Microbiota Restoration Therapy (MRT). The company’s first MRT is a biologic drug targeted at recurrent Clostridium difficile infection.
Rebiotix Founder, President, CEO, Privately held biotechnology company founded in 2011 Developing a new category of drugs to harness the human microbiome to treat disease; involves transplantation of live human-derived microbes; first target is recurrent Clostridium difficile infection, Led pioneering work with the US Food and Drug Administration to develop a new classification for the product – RBX2660 – completed Phase 2 clinical testing.
“C. diff. Spores and More
Through their interviews, the C Diff Foundation mission will connect, educate, and empower many worldwide.
Questions received through the show page portal will be reviewed and addressed by the show’s Medical Correspondent, Dr. Fred Zar, MD, FACP, Dr. Fred Zar is a Professor of Clinical Medicine, Vice He
Clostridium difficile disease and the need to stratify patients by disease severity.
To access the C. diff. Spores and More program page and library, please click on the following link: www.voiceamerica.com/show/2441/c-diff-spores-and-more
Take our show on the go…………..download a mobile app today
Programming for C. diff. Spores and More